Skip to main content
OpenTrials

Clinical trial condition

HER2-negative Breast Cancer

Explore clinical trials studying HER2-negative Breast Cancer. Study availability and eligibility vary by location and protocol.

108 public trials 54 recruiting studies
Refine in advanced search Browse all conditions

HER2-negative Breast Cancer trial results

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283

Conditions
Advanced Breast Cancer, Advanced Solid Tumor, Breast Diseases, +20 more
Locations
  • Sarah Cannon Research Institute (Scri) At Health One Denver, Colorado, United States
  • Florida Cancer Specialists and Research Institute Lake Mary, Florida, United States
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View all 63 locations
View Trial Details
Recruiting

Sacituzumab Govitecan In TNBC

NCT04230109

Conditions
Breast Diseases, Breast Neoplasms, ER-negative Breast Cancer, +9 more
Locations
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Massachusetts General Hospital - North Shore Cancer Center Danvers, Massachusetts, United States
View Trial Details
Recruiting

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

NCT05467891

Conditions
HER2-negative Breast Cancer, Hormone Receptor-Positive Breast Cancer, Locoregional Recurrence
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of Arizona Phoenix, Arizona, United States
  • Georgetown University Washington D.C., District of Columbia, United States
  • Orlando Health Cancer Institute Orlando, Florida, United States
View all 21 locations
View Trial Details
Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750

Conditions
Adnexal Diseases, Advanced Malignant Neoplasm, Advanced Solid Tumor, +81 more
Locations
  • University of California Irvine Chao Family Comprehensive Cancer Center Irvine, California, United States
  • University of San Diego Moores Cancer Center La Jolla, California, United States
  • UCLA Jonsson Comprehensive Cancer Center Los Angeles, California, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 77 locations
View Trial Details
Recruiting

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

NCT06756932

Conditions
Breast Diseases, Breast Neoplasms, HER2-negative Breast Cancer, +6 more
Locations
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
  • Md Anderson Cancer Center Houston, Texas, United States
  • Fred Hutchinson Cancer Research Center Seattle, Washington, United States
  • Saint Vincents Hospital Sydney Darlinghurst, New South Wales, Australia
View all 14 locations
View Trial Details
Recruiting

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

NCT05029999

Conditions
Breast Diseases, Breast Neoplasms, HER2-negative Breast Cancer, +5 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Johns Hopkins University Baltimore, Maryland, United States
  • University of North Carolina Chapel Hill, North Carolina, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
View Trial Details

Related conditions